Combretastatin A4

Catalog No.S7783

For research use only.

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

Combretastatin A4 Chemical Structure

CAS No. 117048-59-6

Selleck's Combretastatin A4 has been cited by 3 Publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Other Microtubule Associated Products

Biological Activity

Description Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.
Targets
β-tubulin [1]
0.4 μM(Kd)
In vitro

Combretastatin A4 inhibits the growth of MDA-MB-231, A549, Hela, HL-60, SF295, HCT-8, MDA-MB435, PC3M, OVCAR-8, NCI-H358M, and lymphocyte cells with IC50 of 2.8, 3.8, 0.9, 2.1, 6.2, 5.3, 7.9, 4.7, 0.37, 8, and 3.2 nM, respectively.[1] [2] 1 μM Combretastatin A4 inhibits tubulin polymerization by 35%, and 10 μM nearly completely blocks tubulin polymerization. Combretastatin A4 demonstrates great relative binding capacity, reaching 78% of colchicine binding.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL-5 MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGnHTopEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBUU02HTD21JI1mdGGwb33hJINmdGxibHnu[ZMtKEWGNUC9N{4xOEVvMEig{txO M4fx[FE5PzV|NUC=
A-549 NF7pd4pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3PKfmN6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJGEuPTR7IHz1coch[2G{Y3nuc41iKGOnbHygcIlv\XNuIFXEOVA:OS5{MFWtNFYh|ryP NFr5[pEyQDd3M{Ww
MCF-7 NYXjVpFXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3X1eGN6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJG1ETi15IHLy[YF{fCClYYLjbY5wdWFiY3XscEBtcW6nczygSWQ2OD1|LkiwSU0xPiEQvF2= M1;ZZ|E5PzV|NUC=
HT-29 NGTPepRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NITaOGxEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBJXC1{OTDjc4xwdiCjZHXuc4NiemOrbn;tZUBk\WyuIHzpcoV{NCCHREWwQVEvOjCHLUC2JO69VQ>? NIrYb3oyQDd3M{Ww
MLM melanoma cell NEXDc4tIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn32R5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gUWxOKG2nbHHuc41iKGOnbHygcIlv\XNuIFXEOVA:OS52MFWtNFYh|ryP NWDPRYFoOTh5NUO1NC=>
M14 M2H3T2N6fG:2b4jpZ4l1gSCjc4PhfS=> MkL3TY4hfmm2cn:gZ5l1d3SxeHnjJIFkfGm4aYT5JJdieyC2ZYP0[YQh[WejaX7zeEBpfW2jbjDt[Yxidm:vYTDjZY5k\XJiKF2xOEkh[2WubDDsbY5mNCCJSUWwQVAvODByMTFOwG0> NFvvRW8yOjd{OU[0NC=>
SK-OV3 NInCXXFEgXSxdH;4bYNqfHliYYPzZZk> NYLWPVNNUW5idnn0do8h[3m2b4TvfIlkKGGldHn2bZR6KHSnc4Tl[EBi\2GrboP0JIh2dWGwIH;2ZZJq[W5iY3HuZ4VzKCiVSz3PWlMqKGOnbHygcIlv\SxiR1m1NF0xNjByMEGg{txO Mn7PNVI4Ojl4NEC=
HL60 cells M3fxRmN6fG:2b4jpZ4l1gSCjc4PhfS=> M4fMXFczKGh? MoT4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAxOSEQvF2= MmHqNlA4OzF|NUW=
SK-OV-3 NWDOXGYyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFrwbHM1QCCq NVPwdWU5T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvT2[tN{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAxOTNizszN MnHPNVg4OjJzMke=
HepG2 cells NX\YTIxbS3m2b4TvfIlkcXS7IHHzd4F6 NYLoZWNuS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNuIFnDOVA:OC5yMECxOEDPxE1? MYCxO|EzPzB4MR?=
ZR-75-1 Mnu5R5l1d3SxeHnjbZR6KGG|c3H5 NGnKRnREgXSxdH;4bYNqfHliYXfhbY5{fCCcUj23OU0yKGOnbHygcIlv\SxiSVO1NF0xNjByMEK0JO69VQ>? M3\IbVE4OjR7NkS5
HeLa cell NVr3[ZJCS3m2b4TvfIlkcXS7IHHzd4F6 MlqzR5l1d3SxeHnjbZR6KGGpYXnud5QhUGWOYTDj[YxtKGyrbnWsJGlEPTB;MD6wNFA{KM7:TR?= NVvVbmVWOTd{NEm2OFk>
HCT116 cell MkjaR5l1d3SxeHnjbZR6KGG|c3H5 NVKwNJRvS3m2b4TvfIlkcXS7IHHnZYlve3RiSFPUNVE3KGOnbHygcIlv\SxiSVO1NF0xNjByMEO1JO69VQ>? NF;2d3YyPzJ2OU[0PS=>
KBV1 cells MlPKR5l1d3SxeHnjbZR6KGG|c3H5 M4r3VFczKGh? MnvoR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6geolv[myjc4TpcoUuemW|aYP0ZY51KEuEVkGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMESg{txO MWiyNFc{OTN3NR?=
SKOV3 MV;DfZRwfG:6aXPpeJkh[XO|YYm= M1zDd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMV1Z|IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNFQzKM7:TR?= MVOyOFAyPjByMh?=
SKOV3 cells MmLwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYqzTIF6T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0uRVkOgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NF0xNjByMESyJO69VQ>? M2HHWFI{Pzd{M{C5
HeLa cells M{\NbmN6fG:2b4jpZ4l1gSCjc4PhfS=> NGXTSJJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNFUyKM7:TR?= MWmxPVg4QTd3OB?=
DU145 cells M2rPW2N6fG:2b4jpZ4l1gSCjc4PhfS=> NXPjT|BLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAxPTRizszN M3fq[lI1ODF4MECy
DU145 cells NYDBVJpPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3jOb2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGRWOTR3IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUC9NE4xODB3NDFOwG0> M4XnR|I{Pzd{M{C5
SK-N-BE MoSwVJJwdGmoZYLheIlwdiCjc4PhfS=> M37JT|czKGh? NHXQdZZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBqdiCqdX3hckBUUy2QLVLFJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEC1PEDPxE1? Mn34NlI{Ojl3NkG=
NCIH460 cells NEXmWJNEgXSxdH;4bYNqfHliYYPzZZk> NWfBfFh6PDhiaB?= NYr6PII6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLSES2NEBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECwOkDPxE1? MVOxPFMxOzh2OR?=
KB-VIN10 cells NEfrVXVRem:uaX\ldoF1cW:wIHHzd4F6 MYO3NkBp MYfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuELW\JUlExKGOnbHzzJI93\XJvZYjwdoV{e2mwZzDQMYdxKDF5MD;NSHIyKGGodHXyJFczKGi{czDifUBu\XSqeXzlcoUh[my3ZTDhd5NigSxiSVO1NF0xNjByMEeg{txO NV;wc|M5OjF4NEG3NFA>
HCT116 cells NXjpe2VwS3m2b4TvfIlkcXS7IHHzd4F6 MWK3NkBp MVvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJHs{UF22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBi\nSncjC3NkBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NF0xNjByMEe0JO69VQ>? MWWyNVk2PTR3NB?=
DU145 cells MUfDfZRwfG:6aXPpeJkh[XO|YYm= MkW0OFghcA>? NVqwdG9vS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMEig{txO MnHENVg{ODN6NEm=
RS4:11 cells NETKWodRem:uaX\ldoF1cW:wIHHzd4F6 NWWzRXBtPzJiaB?= M1rMR2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmO0PlEyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTCoN{0pPCx3LXTpcYV1cHmudHjpZZpwdC1{LYnsLU0zNDVvZHnwbIVvgWy2ZYTyZZpwdGm3bTDido9ucWSnIITld5QtKEmFNUC9NE4xODB6IN88US=> NVvq[ZhSOjV5OEW2NFU>
HCT 116 NYDnfmkxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXTBOGY1S2:wY3XueJJifGmxbjD3bIlkcCCycn;keYNmeyB3MDWgbY5pcWKrdHnvckBw\iCpcn;3eIghd2ZiaIXtZY4h[2:ub36geJVud3JiSFPUJFEyPixiSVO1NF0xNjByMEmg{txO M1;6OFEyPzF2NkGz
HeLa cells NVnqSZNOS3m2b4TvfIlkcXS7IHHzd4F6 NYD2N4JUPzJiaB?= MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDy[ZNignW{aX6gZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7LDDJR|UxRTBwMECwPUDPxE1? MkPDNlQ3Pjl6OEi=
BNL 1ME A.7R.1 cells NWPq[pdFS3m2b4TvfIlkcXS7IHHzd4F6 NUjJS3dxS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSk6OIEHNSUBCNjeULkGgZ4VtdHNuIFnDOVA:OC5yMEC5JO69VQ>? NGm5RWEzPTd6NU[wOS=>
Calu6 MlH5VJJwdGmoZYLheIlwdiCjc4PhfS=> NGPCXIs1QCCq NX3DNnRrSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDZYx2PiCjZoTldkA1QCCqcoOgZpkhe3CnY4Tyc5Bpd3SxbXX0dpktKEmFNUC9NE4xODB7NDFOwG0> NYe1dmpSOjF5N{S0PVk>
melanoma B16 cell NFWzRotIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGPp[3FEd26lZX70doF1cW:wIIfobYNpKHC{b3T1Z4V{KDVyJTDpcohq[mm2aX;uJI9nKGe{b4f0bEBw\iCvdYLpcoUhdWWuYX7vcYEhSjF4IHPlcIwhdGmwZTygTWM2OD1yLkCwNUDPxE1? MnHZNVE4OTR4MUO=
DU145 cells M2T4bmN6fG:2b4jpZ4l1gSCjc4PhfS=> NX:5VGN1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= MV[yNFQ6Pjl{Mx?=
HCT116 cells Ml7qVJJwdGmoZYLheIlwdiCjc4PhfS=> NIi0T5o4OiCq NXTKTmxpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VWyCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= NUXMVnpsOjFzMUKxN|A>
HCT15 cells NHX3fotRem:uaX\ldoF1cW:wIHHzd4F6 MWS3NkBp Mof3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxOUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? MV[yNVEyOjF|MB?=
HL60 cells MnK0VJJwdGmoZYLheIlwdiCjc4PhfS=> NIna[Y04OiCq MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? NE[1doYzOTZ4M{OxPS=>
A10 cells NFXJWpJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXqxOIlvPDhiaB?= NVrT[Fl6T3Kxd4ToJIlvcGmkaYTpc44hd2ZicnH0JGEyOCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= NXjseFBNOjJyNESxOlQ>
HUVEC cells NEnwXFRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWq0PEBp NVnxfZFiT3Kxd4ToJIlvcGmkaYTpc44hd2ZiSGXWSWMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? M1[yXlIzODR2MU[0
HL60 cells NGLTTWREgXSxdH;4bYNqfHliYYPzZZk> NYG1dFFRPzJiaB?= M3[zNGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= M3fEOFIzOTN4M{Gy
HL60 cells MkHJVJJwdGmoZYLheIlwdiCjc4PhfS=> MX23NkBp NWryNnhkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN MYKyNlU4QDFzMR?=
NCI-H522 cells MkHiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXy0PEBp M{\EOWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNUKyJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEGg{txO Mki1NlI6QDJzMkK=
MDA-MB-435 cells M2nVSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVH0TFdKPDhiaB?= NYLUVot{T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVQ{PSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= MXGyNlk5OjF{Mh?=
OVCAR3 M4DxdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYGzfnRVPDhiaB?= NVjyUo5xT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKzJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEGg{txO MnH6NlI6QDJzMkK=
NCI/ADR-RES cells M{ftZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUjDdoM1PDhiaB?= MoTLS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKN0GGUj3SSXMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? NVLzenVEOjJ7OEKxNlI>
PC3 cells MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFfKOZc1QCCq NXLYc4R{T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODFizszN NGjkclAzOjl6MkGyNi=>
DU145 cells NH\C[W5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV[0PEBp NEPG[JRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBFXTF2NTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODBzIN88US=> MnrtNlI6QDJzMkK=
MDA-MB-231 cells NHLJU5ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mle0OFghcA>? NUnZdpN[T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= MnO2NlI6QDJzMkK=
CEM cells NGHhdVhEgXSxdH;4bYNqfHliYYPzZZk> NFPGTFU4OiCq NVnVS246S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0WPIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN MXGyNlY4PjJ2Nx?=
HCT116 cells M3rSNWN6fG:2b4jpZ4l1gSCjc4PhfS=> MVK3NkBp MlmyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN NFvldpAzOjZ5NkK0Oy=>
MDA-MB-435 cells MXjDfZRwfG:6aXPpeJkh[XO|YYm= M1rwU|czKGh? NGjI[WVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFM2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP NX7sU3dlOjJ4N{[yOFc>
HaCaT cells NFn1bmdRem:uaX\ldoF1cW:wIHHzd4F6 Ml64RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKYVPhWEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN NFnkOZQzOzB4M{SwNS=>
HL60 cells MWPQdo9tcW[ncnH0bY9vKGG|c3H5 MWC3NkBp NWnpXoFJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP Ml\2NlMyOTdzN{G=
HL60 cells M3\YZXBzd2yrZnXyZZRqd25iYYPzZZk> MoDJO|IhcA>? Ml24RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHmeIVzKDd{IHjyd{BjgSBqMz2oOEw2NWSrbXX0bJltfGirYYrvcE0zNXmuKT2yMFUu\GmyaHXufYx1\XS{YYrvcIl2dSCkcn;tbYRmKHSnc4SsJGlEPTB;MD6wNFEh|ryP M1\O[lI2Pzh3NkC1
HT-29 NFjNOINIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXzGfYhsT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMkmgZ4VtdHNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= NXPqdYY{OjV4OEmxNVE>
HL60 cells MV;Qdo9tcW[ncnH0bY9vKGG|c3H5 MWW3NkBp NXnEZlhPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP Moq5NlA1OjB2M{m=
Hs578T cells MkDGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF[2cmQ1QCCq M4HpT2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGh{PTd6VDDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODBzIN88US=> MWKyNlk5OjF{Mh?=
HL60 cells MYXDfZRwfG:6aXPpeJkh[XO|YYm= M2rWXlczKGh? M4i5bmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= NH[0OoEzOzR2NUS5Oi=>
SKOV3 cells M{jFbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVH4VFB5T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0uRVkOgZ4VtdHNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= NXLuZ4lHOjV4OEmxNVE>
MDA-MB-468 cells M33sUmN6fG:2b4jpZ4l1gSCjc4PhfS=> NH74NnI1KGSjeYO= MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDRiZHH5d{BjgSCPVGOgZZN{[XluIFnDOVA:OC5yMEGxJO69VQ>? MYGyOFIyODVyMx?=
MCF7 cells NE[xSIRRem:uaX\ldoF1cW:wIHHzd4F6 NV22WmtTPzJiaB?= MmC3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbY4hcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyOTFizszN M4Hjc|IzOzJ7NU[x
H460 MoLmR5l1d3SxeHnjbZR6KGG|c3H5 MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIOFYxKGOnbHzzJIJ6KHO3bH\vdohw\GGvaX7lJGIhfGW|dDygTWM2OD1yLkCwNVIh|ryP NXHEV3h4OTh5OEOyNFc>
H460 NVzsTVhLWHKxbHnm[ZJifGmxbjDhd5NigQ>? M4\QOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSES2NEBk\WyuczygTWM2OD1yLkCwNVI1KM7:TR?= NVTRbYNSOTZ5MkK2N|M>
NCI-H460 cells MULDfZRwfG:6aXPpeJkh[XO|YYm= NILQNYk4OiCq M{fadmN6fG:2b4jpZ{Bi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPDZyIHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJJRme3RuIFnDOVA:OC5yMEGzJO69VQ>? MnW1NVg{QTZ6NUe=
OVCAR8 cells M3q5fmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGf2NYs6PiCq M3\t[Gdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GUODDj[YxteyCxdnXy[ZhxemW|c3nu[{BRNWeueXPvdJJwfGWrbjDh[pRmeiB7NjDodpMtKEmFNUC9NE4xODF|IN88US=> NF7yTFIzOjB2NEG2OC=>
NCI/ADR-RES cells Mne4R5l1d3SxeHnjbZR6KGG|c3H5 NF24dJhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lxQVTSMXJGWyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCkeTD0dplx[W5iYnz1[UBmgGOudYPpc44h[XO|YYmsJGlEPTB;MD6wNFE{KM7:TR?= NED3VI0zOzJzNES1Ni=>
OVCAR8 cells NVTxfZF3S3m2b4TvfIlkcXS7IHHzd4F6 NFvNS3g6PiCq NXT5eoh[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hV1[FQWK4JINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEm2JIhzeyCkeTDHbYVue2Fic4ThbY5qdmdvYnHz[YQhdGmpaISgcYlkem:|Y3;wfUwhUUN3ME2wMlAxOTNizszN MmfONlUxOjV7OUG=
NCI/ADR-RES cells Mle1R5l1d3SxeHnjbZR6KGG|c3H5 NW[1U|E1QTZiaB?= MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kwSUSULWLFV{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC5OkBpenNiYomgS4lmdXOjIIP0ZYlvcW6pLXLhd4VlKGyrZ3j0JI1q[3Kxc3PvdJktKEmFNUC9NE4xODF|IN88US=> MVKyOVAzPTl7MR?=
OVCAR8 cells NF[5eplEgXSxdH;4bYNqfHliYYPzZZk> MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDPWmNCWjhiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYomgeJJ6eGGwIHLseYUh\XilbIXzbY9vKGG|c3H5MEBKSzVyPUCuNFAyOyEQvF2= NEnGOpAzOzJzNES1Ni=>
HuTu 80 cells NIjhOHJRem:uaX\ldoF1cW:wIHHzd4F6 MofNO|IhcA>? NFjzV2pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBqdiCqdX3hckBJfVS3IEiwJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGzO{DPxE1? NYS0bYtrOjJ|Mkm1OlE>
K562 cells NH7KXohEgXSxdH;4bYNqfHliYYPzZZk> NIjVRpFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMPTZ{IHPlcIx{NCCLQ{WwQVAvODBzNDFOwG0> NIKxdZEyQTh|N{W5OC=>
NCI/ADR (MDR) cells NXPFNlY4TnWwY4Tpc44h[XO|YYm= NHPPT2hE\WyuIHP5Z4xmKGG{cnXzeEBqdiCQQ1mvRWRTKCiPRGKpJINmdGy|IHL5JIFk[3WvdXzheIlwdiCjdDDHNk9OKHCqYYPlMEBKSzVyPUCuNFAyPSEQvF2= NFfUZogyPjN5N{G4Oy=>
HUVEC MnfnVJJwdGmoZYLheIlwdiCjc4PhfS=> NHzue3hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjVWmVENCCLQ{WwQVAvODBzNTFOwG0> MWqxOlczOjZ|Mx?=
KB cell MkTjVJJwdGmoZYLheIlwdiCjc4PhfS=> MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuEIHPlcIwhdGmwZTDifUBu\XSqeXzlcoUh[my3ZTDkfYUh[XO|YYmsJGlEPTB;MD6wNFE2KM7:TR?= M1\qXFE4ODN2MUS3
KB-VIN10 cell MmXPVJJwdGmoZYLheIlwdiCjc4PhfS=> NVG3OVZMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRk1XUU5zMDDj[YxtKGyrbnWgZpkhdWW2aIns[Y5mKGKudXWg[JlmKGG|c3H5MEBKSzVyPUCuNFAyPSEQvF2= NFf6Om0yPzB|NEG0Oy=>
Human SH-SY5Y neuroblastoma cells NVm3bnVMTnWwY4Tpc44h[XO|YYm= NYLtdWFWUW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgTJVu[W5iU1itV3k2YSCwZYXyc4Jt[XO2b33hJINmdGy|LDDJR|UxRTBwMECxOUDPxE1? MnvGNVU6PjN5MkK=
SW620 cells Mly1VJJwdGmoZYLheIlwdiCjc4PhfS=> NEW2XWY4OiCq NYPxdFYySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcW5iaIXtZY4hW1d4MkCgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMUWyJO69VQ>? NF7mSFgzOjN{OUW2NS=>
Molt4/C8 cells M4PX[3Bzd2yrZnXyZZRqd25iYYPzZZk> NYS2SosySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNc4x1PC:FODDj[YxteyxiSVO1NF0xNjByMU[g{txO NU\zZZZHOTdyM{SxOVA>
ACHN cell MojYVJJwdGmoZYLheIlwdiCjc4PhfS=> M2PPcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[JJ2\yC{ZYPpd5RidnRiQVPIUkBk\WyuIHzpcoUh\XiycnXzd4lv\yCPRGKxJIJ6KEGuYX3hdkBDdHWnIHHzd4F6NCCLQ{WwQVAvODBzNjFOwG0> MXOxO|I5PjN7Mx?=
Molt4/C8 cells M3;wcXBzd2yrZnXyZZRqd25iYYPzZZk> NWnobYlLOyCmYYnz M4rKXGFvfGmycn;sbYZmemG2aY\lJIVn\mWldDDh[4FqdnO2IHj1cYFvKE2xbIS0M2M5KGOnbHzzJIFnfGW{IEOg[IF6eyxiSVO1NF0xNjByMU[g{txO NGjrfHMyPzRzOU[wOy=>
In vivo In NT2 and MDA-MB-231 mammary tumor model, administration of Combretastatin A4 (100 mg/kg, i.p.) induces a significant decrease in lipids R1 and a reduction in tumor pO2 measured by electron paramagnetic resonance (EPR) oximetry.[2] Combretastatin A4 (100 mg/kg, i.p.) significant decreases the Ktrans in male NMRI mice.[3]

Protocol (from reference)

Kinase Assay:[1]
  • Competitive binding assay using LC-MS/MS:

    Colchicine (1.2 μ M) is incubated with tubulin (1.3 mg/mL) in the incubation buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9) at 37℃ for 1 h. Varying concentrations (0.1 − 125 μ M) of Combretastatin A4 are used to compete with colchicine originally bound to tubulin. After incubation, the filtrate is obtained. The ability of the analogue to inhibit the binding of colchicine is expressed as a percentage of control binding in the absence of any competitor.

Cell Research:[1]
  • Cell lines: MDA-MB-231, A549, and Hela cells
  • Concentrations: ~3.8 nM
  • Incubation Time: 72 h
  • Method: MDA-MB-231, A549, and HeLa cells are grown in DMEM medium (115 units/mL of penicillin G, 115 μg/mL of streptomycin, and 10% fetal bovine serum). Cells are seeded in 96-well plates (5000 cells/well) containing 50 μL of growth medium for 24 h. After medium removal, 100 μL of fresh medium containing individual analogue compounds at different concentrations is added to each well and incubated at 37 ℃ for 72 h. After 24 h of culture, the cells are supplemented with 50 μL of analogue compounds dissolved in DMSO (less than 0.25% in each preparation). After 72 h of incubation, 20 μL of resazurin is added for 2 h before recording fluorescence at 560 nm (excitation) and 590 nm (emission) using a Victor microtiter plate fluorimeter. The IC50 is defined as the compound concentration required to inhibit cell proliferation by 50% in comparison with cells treated with the maximum amount of DMSO (0.25%) and considered as 100% viability.
  • (Only for Reference)
Animal Research:[2]
  • Animal Models: FVB/N or nude NMRI female mice bearing NT2 and MDA-MB-231 tumors
  • Dosages: 100 mg/kg
  • Administration: i.p.
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 63 mg/mL
(199.14 mM)
Ethanol 34 mg/mL warmed
(107.47 mM)
Water Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+50% PEG 300+ddH2O
For best results, use promptly after mixing.

30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 316.35
Formula

C18H20O5

CAS No. 117048-59-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC1=C(C=C(C=C1)C=CC2=CC(=C(C(=C2)OC)OC)OC)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
How to make solution for in vivo IP injection?

Answer:
We've tested some vehicles for S7783 Combretastatin A4, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve the compound in DMSO clearly first. The add PEG, after they mixed well, then dilute with water.

Tags: buy Combretastatin A4 | Combretastatin A4 supplier | purchase Combretastatin A4 | Combretastatin A4 cost | Combretastatin A4 manufacturer | order Combretastatin A4 | Combretastatin A4 distributor